CHF Solutions Convene Physicians to Discuss Cardio-Pulmonary-Renal Management of COVID-19 Patients
April 08 2020 - 9:15AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload, today
announced the company will host an interactive, clinician-led
webinar to discuss cardio-pulmonary-renal management in real-world
COVID-19 patients. Dr. Daniel J. Goldstein, Professor & Vice
Chairman, Department of Cardiothoracic Surgery, Montefiore Medical
Center, New York will moderate the online discussion on Friday,
April 10 at 1:00 p.m. EDT.
Clinicians will present COVID-19 Case Studies in a grand rounds
format and discuss:
- Complex fluid balance and fluid overload management
- Strategies for managing cardio-pulmonary status and hemodynamic
state
- Managing the continuum of acute kidney injury (AKI) through
end-stage renal disease (ESRD)
- Current strategies for treating ARDS, minimizing ventilation
time and the role of prone positioning
- Staffing and resource challenges
- Lessons learned
Webinar Details
Moderator: Daniel J. Goldstein, MD, FACS, FACC, Montefiore
Medical Center, New York City, NY
Physicians Presenting Patient Case Studies:
- Maria DeVita, MD, FACP, FASN, Nephrologist, The Lenox Hill
Hospital, New York City, NY
- Mehdi Oloomi, MD, Intensivist, The Mount Sinai Hospital, New
York City, NY
- Giovanni Piovesana, MD, Cardio-Thoracic Surgeon, Phoebe Putney
Hospital, Albany, GA
“As providers look for real-world evidence to improve outcomes
for critically-ill patients with COVID-19, it’s important that we
convene and speed access to communication from the front lines of
care,” said Daniel J. Goldstein, MD, FACS, FACC, of Montefiore
Medical Center. “One of the many clinical challenges we are facing
is to look at what we are learning about cardio-pulmonary-renal
management and this group of experienced physicians can share what
they are observing in their patients.”
“Our dedication to helping treat patients during this pandemic
continues to drive the decision we are making,” said John Erb, CEO
of CHF Solutions. “We have been hearing from distinguished
physicians that our ultrafiltration therapy has aided in the
treatment of patients with COVID-19. Our hope is that sharing these
patient case studies from treating physicians will equip other
providers with information that will help them provide the best
possible care during this unprecedented time.”
Register to participate in this informative webinar by following
this link: https://bit.ly/3b31kM5.
For those unable to attend the webinar, an audio archive of the
webcast will be available at http://ir.chf-solutions.com/ events
within 48 hours of the event.
About CHF Solutions CHF Solutions, Inc.
(Nasdaq: CHFS) is a medical device company dedicated to improving
the lives of patients suffering from fluid overload with its novel
ultrafiltration therapy system. The company is focused on
developing, manufacturing and commercializing the Aquadex SmartFlow
system for ultrafiltration therapy. CHF Solutions is headquartered
in Minneapolis, Minn., with wholly-owned subsidiaries in Australia
and Ireland. The company has been listed on the Nasdaq Capital
Market since February 2012.
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements about the treatment
of patients infected with the coronavirus COVID-19. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024